Produção Nacional
Revisado por pares
Consenso expandido do BCTRIMS para o tratamento da esclerose múltipla: I. As evidências para o uso de imunossupressores, plasmaférese e transplante autólogo de células tronco
2002; Thieme Medical Publishers (Germany); Volume: 60; Issue: 3B Linguagem: Inglês
10.1590/s0004-282x2002000500035
ISSN1678-4227
AutoresDagoberto Callegaro, Marco Aurélio Lana–Peixoto, Marcos Aurélio Moreira, Paulo Eurípedes Marchiori, Luiz Alberto Bacheschi, Walter Oleschko Arruda, Gilberto Belisário Campos, Angelina Maria Martins Lino, Aílton Souza Melo, Maria Sheila Guimarães Rocha, Maria Lúcia Brito Ferreira, L.A. Forgiarini Júnior, Damácio Ramón Kaimén Maciel,
Tópico(s)Polyomavirus and related diseases
ResumoSince the sixties immunosuppressive agents have been used in the treatment of multiple sclerosis as there was cumulating evidence of the inflammatory nature of the disease. Cyclophosphamide, azathioprine and methotrexate have been the most frequently employed drugs whereas other agents such as cyclosporine and cladribine have been recently tested for RRMS. Mithoxantrone, on the other hand, was approved by the FDA for treatment of aggressive forms of the disease. Other immunointerventions such as plasma exchange and autologous hematopoietic stem cell transplantation have recently been employed in some special circumstances. This paper analyses the most important published data on the use of the immunosuppressive agents, plasma exchange and autologous hematopoietic stem cell transplantation according to the classes of evidences and types of recommendations of these drugs and immunointerventions. It provides sufficient information to support the guidelines expressed in the BCTRIMS Expanded Consensus on Treatment of MS.
Referência(s)